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Abstract
Introduction: In animal models of systemic inflammation, the endogenous nucleoside adenosine controls
inflammation and prevents organ injury. Dipyridamole blocks the cellular uptake of endogenous adenosine and
increases the extracellular adenosine concentration. We studied the effects of oral dipyridamole treatment on
innate immunity and organ injury during human experimental endotoxemia.
Methods: In a randomized double-blind placebo-controlled study, 20 healthy male subjects received 2 ng/kg
Escherichia coli endotoxin (lipopolysaccharide; LPS) intravenously after 7-day pretreatment with dipyridamole, 200
mg slow release twice daily, or placebo.
Results: Nucleoside transporter activity on circulating erythrocytes was reduced by dipyridamole with 89% ± 2% (P
< 0.0001), and the circulating endogenous adenosine concentration was increased. Treatment with dipyridamole
augmented the LPS-induced increase in the antiinflammatory cytokine interleukin (IL)-10 with 274%, and resulted
in a more rapid decrease in proinflammatory cytokines tumor necrosis factor-a (TNF-a) and IL-6 levels directly after
their peak level (P < 0.05 and < 0.01, respectively). A strong correlation was found between the plasma
dipyridamole concentration and the adenosine concentration (r = 0.82; P < 0.01), and between the adenosine
concentration and the IL-10 concentration (r = 0.88; P < 0.0001), and the subsequent decrease in TNF-a (r = -0.54;
P = 0.02). Dipyridamole treatment did not affect the LPS-induced endothelial dysfunction or renal injury during
experimental endotoxemia.
Conclusions: Seven-day oral treatment with dipyridamole increases the circulating adenosine concentration and
augments the antiinflammatory response during experimental human endotoxemia, which is associated with a
faster decline in proinflammatory cytokines.
Trial registration: ClinicalTrials (NCT): NCT01091571.
Introduction
During sepsis, unopposed and prolonged activation of
the innate immune system can induce significant collat-
eral damage to host tissues, resulting in a high mortality
rate. During inflammation, the extracellular concentra-
tion of the purine nucleoside adenosine rapidly increases
[1-3]. Subsequent receptor activation acts as a physiolo-
gical negative-feedback mechanism that dampens the
inflammatory response [4]. Indeed, administration of
adenosine-receptor agonists exerts antiinflammatory and
tissue-protective effects and reduces mortality in animal
models of systemic inflammation [5,6].
Dipyridamole blocks the equilibrative nucleoside
transporter (ENT), which facilitates the transmembra-
nous diffusion of adenosine (Figure 1). Dipyridamole
will increase the extracellular endogenous adenosine
concentration, mainly in situations of increased extracel-
lular formation of adenosine, such as occurs during
hypoxia or inflammation [7]. In animals, the administra-
tion of ENT blockers attenuates LPS-induced leukopenia
and tumor necrosis factor-a (TNF-a)p r o d u c t i o n[ 8 ]
and reduces the severity of tissue injury in several
inflammatory models [9-11]. * Correspondence: p.pickkers@ic.umcn.nl
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the excessive and prolonged activation of the immune
response that can occur during systemic inflammation.
Therefore, in a proof-of-concept study in healthy volun-
teers, we examined whether pretreatment with dipyrida-
mole curtails the activation of the innate immune
system during experimental endotoxemia and prevents
(subclinical) organ damage.
Materials and methods
Healthy volunteers
This study was approved by the local ethics committee
and registered (http://www.clinicaltrials.gov, NCT01
091571). After signing for informed consent, 20 healthy
male volunteers participated. Because of significant dif-
ferences in the innate immune response between male
and female subjects during experimental endotoxemia,
we included only male subjects [12]. All volunteers were
asked not to take any drugs or caffeine-containing
substances 48 hours before the start of the endotoxemia
experiment. Subjects were randomized in a double-
blinded fashion to 7-day pretreatment with dipyridamole
(200 mg BID orally, Persantin Retard; Boehringer-Ingel-
heim, Alkmaar, The Netherlands; n = 10) or placebo
(microcrystalline cellulose, n = 10), based on the fact
that a steady state occurs after 3 days, and previous stu-
dies that examined the effects of dipyridamole during
ischemia were also performed after 7 days of treatment
[13]. Oral dipyridamole and placebo capsules were pro-
vided and labeled by the Department of Clinical Phar-
macy of the Radboud University Nijmegen Medical
Center according to GMPstandards. Both capsules had
the same appearance.
Experimental protocol
After local anesthesia, the brachial artery of the nondo-
minant arm was cannulated for blood pressure monitor-
ing, blood sampling, and administration of vasoactive
Figure 1 Schematic representation of the adenosine metabolism. Dipyridamole acts as an adenosine reuptake inhibitor through inhibition
of the nucleoside transporter. ADP, adenosine diphosphate; AMP, adenosine monophosphate; ATP, adenosine triphosphate; SAH, S-
adenosylhomocysteine.
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cubital vein for prehydration [15]. U.S. Reference E. coli
endotoxin (Escherichia coli O:113; Clinical Center Refer-
ence Endotoxin, National Institutes of Health, Bethesda,
MD (LPS)) was administered as a bolus infusion in 1
minute (2 ng/kg) at t = 0 hours, after vortex mixing for
30 minutes. The protocol is illustrated in Figure 2.
Analytic procedures
Plasma caffeine and dipyridamole concentrations were
determined by reversed-phase high-power liquid chro-
matography (HPLC) [16]. Circulating adenosine concen-
trations were measured before and during endotoxemia,
and the activity of the ENT was measured in isolated
erythrocytes by measuring uridine uptake, as previously
described [13,17]. Concentrations of tumor necrosis fac-
tor (TNF)-a, interleukin (IL)-6, IL-1 receptor antagonist
(IL1ra), IL-10, intercellular adhesion molecule 1 (ICAM-
1), and vascular adhesion molecule 1 (VCAM-1) were
analyzed in batches by using a Luminex assay (Bio-plex
cytokine assay; BioRad, Hercules, CA, USA). The antiox-
idant capacity in blood plasma was measured by using
the ferric reducing ability of plasma (FRAP) assay,
according to the method of Benzie and Strain [18].
Forearm blood-flow measurements
Forearm blood flow (FBF, milliliters per minute per dec-
iliter forearm volume) was measured 2 hours before and
4 hours after LPS administration with venous occlusion
plethysmography (Filtrass Domed, Munich, Germany)
[19]. The vasodilator response to intrabrachial infusion
of acetylcholine (5, 20, 80 μg/min/dl) and nitroprusside
( 0 . 6 ,2 ,6μg/min/dl), and the vasoconstrictor response
to norepinephrine (0.03, 0.1, 0.3 μg/min/dl) was quanti-
fied [20]. Infusion rates of drugs and measurements of
forearm blood volume were normalized to forearm
blood volume and expressed per deciliter of forearm
volume.
Drugs and solutions
Acetylcholine (Novartis Pharma, Nurnberg, Germany)
and norepinephrine (Centrafarm BV, Etten-Leur, The
Netherlands) were dissolved in normal saline, and nitro-
prusside (Clinical Pharmacy, Radboud University Nijme-
gen Medical Centre) was dissolved in a 5% glucose
solution. All solutions were freshly prepared at the day
of the experiment.
Urine collection
Subjects collected their morning urine before treatment
with dipyridamole or placebo and on the day of the LPS
experiment. After start of the LPS infusion, urine was
collected in four 3-hour periods and during a period of
12 to 24 hours (see Figure 2). During the sampling per-
iod, urine was kept on ice. Urine volume was measured,
and creatinine, glutathione S-transferase (GST) alpha
(A1-1) and pi (P1-1), as markers of proximal and distal
tubule injury, respectively, were measured [21].
Statistical analyses
The effect of dipyridamole was analyzed by using a
repeated measures analysis of variance (ANOVA), with
post hoc tests for specific time points (Bonferroni).
Further to substantiate the possible mechanism of action
Figure 2 Schematic presentation of the endotoxemia experiments.
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explore the correlation between plasma levels of dipyri-
damole, adenosine, and cytokines. The lines were calcu-
lated from linear regression analyses.
T h ea r e au n d e rt h ec u r v e( A U C )o ft h ei n c r e a s ei n
FBF was calculated (before and after LPS administra-
tion). The LPS-mediated difference was compared
between groups by using an unpaired Student t test.
The effect of endotoxemia on FRAP was tested by using
a repeated measures ANOVA. Because data had a gaus-
sian distribution, data are expressed as mean ± SEM,
unless specified otherwise. Nonparametric data are illu-
strated as box-and-whiskers. A P value < 0.05 was con-
sidered statistically significant.
Results
Demographic characteristics
The demographic characteristics were comparable
between groups (Table 1). Plasma caffeine concentra-
tions immediately before LPS administration were <
0.06 mg/L in both the dipyridamole and the placebo
groups. The incidence of side effects was not signifi-
cantly different between the dipyridamole and the pla-
cebo groups.
Effect of dipyridamole on circulating adenosine
The plasma dipyridamole concentration at the moment
of LPS administration (t =0 )a v e r a g e d1 . 8±0 . 3a n d0 . 0
± 0.0 mg/L for the dipyridamole and placebo groups,
respectively.
U r i d i n eu p t a k ei n t ot h ee r ythrocyte via the ENT was
profoundly inhibited by dipyridamole: from 113 ± 9
nmol/10
9 erythrocytes/min at baseline to 11 ± 2 nmol/
10
9 erythrocytes/min immediately before the LPS
experiment (P < 0.0001). In placebo-treated subjects,
uridine transport was 112 ± 7 nmol/10
9 erythrocytes/
min at baseline and 124 ± 7 nmol/10
9 erythrocytes/min
immediately before the LPS experiment (P = 0.86).
Seven-day treatment with dipyridamole resulted in a
higher adenosine concentration before the LPS adminis-
tration; 22.6 ± 2.7 nmol/ml compared with 11.1 ± 1.8
nmol/ml in the placebo group (P < 0.01). The adenosine
concentration further increased with 2.1 ± 2.8 and 2.1 ±
0.9 nmol/ml after administration of LPS in both groups
(P = 0.99, difference between both groups). Dipyrida-
mole concentrations correlated strongly with peak ade-
nosine concentrations (r = 0.82; P < 0.01, see Figure 3a).
Innate immune response
Inflammatory parameters during human endotoxemia
During the first hour after LPS administration, the total
white blood cell count decreased from 6.2 ± 0.3 to 2.2 ±
0.3 × 10
9/L and from 5.7 ± 0.6 to 2.2 ± 0.3 × 10
9/L for
dipyridamole- and placebo-treated subjects, after which
there was an increase to 13.6 ± 0.7 × 10
9/L and 11.9 ±
0.6 × 10
9/L at 8 hours after LPS (P = 0.07). Dipyrida-
mole-treated subjects had significantly higher amounts of
circulating monocytes in the period of 4 to 8 hours after
LPS, with a peak at 8 hours after LPS administration
(0.64 ± 0.08 × 10
9/L in dipyridamole-treated subjects ver-
sus 0.37 ± 0.03 × 10
9/L in placebo; P =0 . 0 4 ) .T h e
increase in body temperature after administration of LPS
was similar in the dipyridamole and placebo groups; from
36.5°C ± 0.1°C to 38.0°C ± 0.2°C and from 36.4°C ± 0.1°C
to 38.2°C ± 0.1°C, respectively (P = 0.76 between groups).
Dipyridamole treatment augmented the IL-10
response during endotoxemia (P < 0.0001 compared
with the placebo group; Figure 4). Moreover, the endo-
genous adenosine concentration 2 hours after LPS
administration correlated with peak levels of IL-10 (r =
0.88; P < 0.0001), as illustrated in Figure 3b. The LPS-
induced peak concentrations of proinflammatory cyto-
kines were not influenced by dipyridamole treatment. In
contrast, the decline of TNF-a and IL-6 levels directly
after their highest value was accelerated in dipyrida-
mole-treated subjects (P < 0.05 and < 0.01, respectively;
Figure 4). The peak IL-10 levels correlated with the
decline of TNF-a (r = -0.54; P = 0.02), but not with that
of IL-6 (r = -0.32; P = 0.18), Figure 3c and 3d.
LPS-induced end-organ dysfunction
Clinical and hemodynamic parameters during human
endotoxemia
In all volunteers, LPS administration induced the
expected flu-like symptoms. Experimental endotoxemia
resulted in a vasodilatory state, illustrated by a decrease
in blood pressure and an increase in heart rate and fore-
arm blood flow, with a maximum effect at t =4t o6
hours after LPS administration (Table 2). This LPS-
induced cardiovascular response was similar between
groups.
FBF response to acetylcholine, nitroprusside and
norepinephrine
Subjects treated with dipyridamole had a lower baseline
FBF (2.7 ± 0.4 versus 4.3 ± 0.5 ml/min/dl in placebo-
Table 1 Demographic characteristics
Placebo (n =
10)
Dipyridamole (n =
10)
Age (years) 21.4 ± 1.8 22 ± 2.6
Height (m) 1.86 ± 0.1 1.84 ± 0.1
Weight (kg) 84.4 ± 10.6 75.8 ± 8.5
BMI (kg/m
2) 24.5 ± 3.9 22.3 ± 1.9
Heart rate (beats per
minute)
62 ± 7 60 ± 5
MAP (mm Hg) 96 ± 4 91 ± 7
Forearm volume (ml) 1,190 ± 124 1,033 ± 96
Data reported as mean ± SD.
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disappeared after LPS administration: 7.3 ± 0.8 in the
dipyridamole group versus 8.6 ± 1.2 ml/min/dl in the
placebo group. No significant changes in FBF were
found in the noninfused forearm during the intrabra-
chial infusions of acetylcholine, nitroprusside, and nore-
pinephrine, excluding systemic hemodynamic effects of
these drugs. As shown in Figure 5, endothelium-depen-
dent (a) and independent vasodilatation (b) as well as
norepinephrine-induced vasoconstriction (c) were signif-
icantly impaired after endotoxemia. No significant differ-
ences were noted between the treatment groups.
Circulating adhesion molecules
Baseline plasma levels of ICAM and VCAM tended to
be higher in dipyridamole-treated subjects (ICAM:
dipyridamole, 12.0 ± 0.7 × 10
4 pg/ml, versus placebo,
10.0 ± 0.7 × 10
4 pg/ml (P = 0.05); VCAM: dipyrida-
mole, 19.1 ± 1.2 × 10
4 pg/ml versus placebo, 16.5 ±
0.7 × 10
4 pg/ml (P = 0.08)). Both ICAM and VCAM
levels increased after LPS administration (P < 0.0001),
but dipyridamole treatment did not affect the endotox-
emia-induced increase in ICAM and VCAM levels (dif-
ference between groups: P =0 . 3 1a n dP =0 . 9 0 ,
respectively).
Oxidative stress
The total antioxidant capacity, as measured with FRAP,
increased during the first 2 hours after endotoxemia
from 0.96 ± 0.04 to 1.00 ± 0.03 mmol/L and from 1.06
± 0.05 to 1.16 ± 0.05 mmol/L (P =0 . 0 8a n dP =0 . 0 2
for dipyridamole and placebo groups, respectively). No
significant difference in FRAP was found between both
groups (P = 0.36; Figure 6).
Renal injury
Endotoxemia resulted in a cumulative GSTA1-1 excre-
tion of 11.2 (6.2 to 13.0) μg compared with 5.1 (3.9 to
9.4) μg 12 hours after LPS administration in
Figure 3 Correlations between (a) the dipyridamole concentration at the moment of LPS administration and the (peak) adenosine
concentration, 2 hours after LPS administration; (b) the peak adenosine concentration and peak IL-10 levels; (c) peak IL-10
concentrations and the decline in TNF-a levels (t =2t ot = 90 minutes after LPS administration); and (d) peak IL-10 concentrations
and the decline in IL-6 levels.
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tively. Cumulative GSTP1-1excretion was 6.4 (5.4 to
7.8) μg and 6.3 (4.5 to 8.0) μg, respectively. No differ-
ences were seen between the LPS-induced increase
between both groups (P =0 . 0 7a n dP =0 . 4 4 ,
respectively).
Discussion
In the current study, we showed for the first time in
humans in vivo that oral treatment with the nucleoside
transport inhibitor dipyridamole augments the anti-
inflammatory response of the innate immune system
during experimental endotoxemia. Treatment with
Figure 4 B o x - a n d - w h i s k e r s( w h i s k e r s ,r a n g e )o ft h ec y t o k i n er e s p o n s ea f t e rL P Sa d m i n i s t r a t i o ni np l a c e b o - t r e a t e ds u b j e c t s( o p e n
symbols) and dipyridamole-treated subjects (solid symbols), n = 10 subjects per group. The probability values refer to the statistical
difference between the placebo- and dipyridamole-treated groups in response to LPS administration, as analyzed with a two-way ANOVA. *P <
0.05 between groups, as analyzed with a Bonferroni posttest.
Table 2 Hemodynamic profile in response to endotoxemia
Placebo Dipyridamole Difference between groups
Baseline 4 to 6 hours after LPS Baseline 4 to 6 hours after LPS (P value)
HR (beats per minute) 65 ± 2 84 ± 2 67 ± 2 89 ± 1 0.59
SBP (mm Hg) 132 ± 1 121 ± 2 134 ± 2 114 ± 2 0.29
DBP (mm Hg) 76 ± 1 71 ± 2 74 ± 1 68 ± 1 0.6
MAP (mm Hg) 94 ± 1 87 ± 2 94 ± 1 83 ± 1 0.35
FBF ml/min/dl 2.7 ± 0.4 7.3 ± 0.8 4.3 ± 0.5 8.6 ± 1.2 0.87
Data expressed as mean ± SEM. DBP, diastolic blood pressure; FBF, forearm blood flow; HR, heart rate; MAP, mean arterial pressure; SBP, systolic blood pressure.
All LPS-induced changes were significant (P < 0.0001).
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Page 6 of 10Figure 5 Dose-response curve of intrabrachial infusion of (a) acetylcholine, (b) nitroprusside, and (c) norepinephrine on forearm blood
flow (FBF) before (open symbols, dotted line) and 4 hours after administration of 2 ng/kg Escherichia coli LPS (solid symbols). Data are
presented as percentages of baseline FBF of the intervention arm (mean ± SEM; n = 10 per group). Left panel shows placebo-treated subjects;
right panel, subjects treated with dipyridamole. The probability values refer to the statistical difference between the dose-response curves, as
analyzed with two-way ANOVA.
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resulted in a significant increase in the circulating endo-
genous adenosine concentration. In the dipyridamole-
treated subjects, the antiinflammatory IL-10 response to
LPS administration was highly augmented, and was
associated with an accelerated decline of the proinflam-
matory cytokines TNF-a and IL-6 after their initial
increase. We demonstrated that dipyridamole concentra-
tions correlated with adenosine concentrations, that
higher adenosine concentrations were associated with
higher IL-10 concentrations, and that higher IL-10 levels
were associated with a more pronounced decline of
TNF-a. These subsequent correlations suggest that the
immunomodulating effects of dipyridamole are mediated
through the adenosine pathway.
T h ep u r i n en u c l e o s i d ea d e n o s i n ei saw e l l - k n o w n
endogenous signaling molecule with potent antiinflam-
matory and tissue-protective properties [1,22,23]. During
systemic inflammation, the endogenous adenosine con-
centration rapidly increases [3,24], with circulating con-
centrations doubled during experimental human
endotoxemia [17] and increasing up to tenfold in septic
shock patients [3]. However, interpretation of these
measurements must be addressed with caution, because
adenosine measurement is notoriously troublesome [25].
Subsequent stimulation of membrane-bound adenosine
receptors may act as a negative-feedback mechanism to
control and curtail the inflammatory response and to
attenuate further organ damage. Indeed, animal studies
previously showed that adenosine plays a pivotal role in
the protection of tissue against damage from excessive
inflammation (for example, during sepsis [4,5]). In addi-
tion, the administration of adenosine-receptor agonists
potently limits inflammation in murine models of sys-
temic inflammation [5,6]. Human data on the role of
adenosine during systemic inflammation are scarce.
Continuous intravenous administration of adenosine
attenuated the IL-6 response during human endotoxe-
mia [26]. However, therapeutic administration of adeno-
sine is cumbersome, because of the extremely short
half-life of adenosine, the hemodynamic effects during
systemic administration, and because the endothelium
acts as a strong metabolic barrier for adenosine, pre-
venting adenosine from entering the interstitial com-
partment [27]. As such, the plasma concentration of
adenosine does not represent tissue interstitial concen-
trations of adenosine. This is relevant, because resident
tissue macrophages appear to be the major source of
circulating cytokines. By preventing cellular uptake of
adenosine, dipyridamole increases the endogenous extra-
cellular adenosine concentration mainly in those tissues
where extracellular adenosine formation is increased
(that is, at the site of inflammation). Therefore, we
hypothesized that dipyridamole controls inflammation
more effectively than does exogenous adenosine, with
fewer hemodynamic side effects.
Our results are in accordance with previous in vitro
and animal experiments on the immunomodulating
effect of nucleoside transport inhibition. Dipyridamole
enhances the LPS-induced IL-10 production [28] and
attenuates the production of TNF-a [29] and other
proinflammatory cytokines in human cultured mono-
nuclear cells. Furthermore, dipyridamole therapy in
patients undergoing coronary artery bypass grafting
inhibited postoperative ex vivo polymorphonuclear cell
adhesion to endothelial cells [30]. Also in animal stu-
dies, administration of ENT inhibitors limited the
inflammatory response and reduced tissue injury in
situations of severe inflammation [9-11]. Of importance,
these effects were abolished by concomitant administra-
tion of adenosine A2a receptor antagonists [31].
The immune-modulating effects of dipyridamole are
sparsely studied in humans in vivo.W eh a v ep r e v i o u s l y
shown that dipyridamole reduces ischemia-reperfusion
injury in healthy volunteers[ 1 3 ] .T oo u rk n o w l e d g e ,
apart from a small study in patients with rheumatoid
arthritis [32], dipyridamole has never been tested in
situations of generalized inflammation. In this latter
study, dipyridamole was not found to reduce inflamma-
tion [32], but a clear conclusion is not possible, as it
appears likely that this study was underpowered.
In our study, treatment with dipyridamole profoundly
enhanced the antiinflammatory IL-10 response during
endotoxemia. IL-10 is produced by cells of the innate
immune system and is able to inhibit the synthesis of
Figure 6 Box-and-whiskers (whiskers, range) of the
endotoxemia-induced changes in FRAP. FRAP increases during
endotoxemia, in both dipyridamole- and placebo-treated subjects (P
= 0.08 and 0.02, respectively). No differences between groups were
found, as analyzed with two-way ANOVA (P = 036).
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an autoregulatory fashion [33]. In accordance, adminis-
tration of IL-10 protects mice from lethal endotoxemia
[34], and IL-10 knockout mice have a more-pronounced
hemodynamic response to LPS administration [35].
Given the strong association between the plasma adeno-
sine and IL-10 concentration, we propose that dipyrida-
mole augments the IL-10 response by increasing the
endogenous adenosine concentration. Indeed, animal
studies have shown that adenosine-receptor agonists
augment the IL-10 response to LPS [6]. In accordance
with the antiinflammatory role of IL-10, we observed a
more-rapid decrease in plasma TNF-a and IL-6 after
the peak concentrations of these proinflammatory cyto-
kines. In contrast, peak plasma levels of TNF-a and IL-
6 were not affected by dipyridamole. It appears plausible
that this initial proinflammatory response is needed as a
stimulus for increased adenosine formation at the site of
inflammation. Dipyridamole may therefore enhance the
antiinflammatory properties of adenosine only directly
after the initial proinflammatory insult. In our study,
dipyridamole increased the baseline plasma adenosine
concentration, but did not augment the LPS-induced
increase in adenosine. This may be explained by the fact
that adenosine can be highly compartmentalized, as
described earlier.
Despite the observation that treatment with dipyrida-
mole modulates the plasma cytokine response during
endotoxemia toward a more antiinflammatory profile,
this treatment did not prevent LPS-induced vascular
dysfunction and renal injury, nor did it influence the
LPS-induced increase in FRAP. Our observation that
endotoxemia increases FRAP concentrations is in accor-
dance with a previously described FRAP increase
observed in sepsis patients [36]. We postulate that this
lack of an effect on organ injury is due to the relatively
mild and short-lasting inflammatory insult induced dur-
ing experimental endotoxemia, and it may not rule out
the possibility that the antiinflammatory effects of dipyr-
idamole prevent organ dysfunction in the setting of a
more severe or more persistent proinflammatory insult,
such as during sepsis or autoimmune diseases.
Given the fact that dipyridamole treatment has limited
side effects and modulates the innate immune response
to a relevant extent, further studies are warranted to
explore the immunomodulating potential in patients
with systemic inflammation.
Conclusions
Seven-day oral treatment with dipyridamole is associated
with increased circulating levels of adenosine and an
augmented antiinflammatory response during human
experimental endotoxemia that may curtail the release
of proinflammatory cytokines.
Key messages
◆ Seven-day treatment with dipyridamole increases
the endogenous adenosine concentration and aug-
ments the antiinflammatory response during human
experimental endotoxemia.
◆ A strong correlation exists between the dipyrida-
mole concentration and the endogenous adenosine
concentration, which in turn correlates with the IL-
10 response.
◆ The more-pronounced increase in IL-10 is asso-
ciated with an accelerated decline of proinflamma-
tory cytokines.
◆ Immunomodulating properties of dipyridamole
may be of therapeutic benefit in patients with severe
or persisting systemic inflammation.
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